Bioventus Inc.
BVS
$8.97
-$0.18-1.97%
NASDAQ
| 12/31/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.77% | -0.23% | -2.35% | -4.31% | 13.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.77% | -0.23% | -2.35% | -4.31% | 13.45% |
| Cost of Revenue | -3.66% | -2.18% | -4.22% | -0.63% | 3.79% |
| Gross Profit | 5.97% | 0.72% | -1.49% | -6.02% | 18.95% |
| SG&A Expenses | -4.65% | -3.42% | -6.02% | -6.72% | 10.76% |
| Depreciation & Amortization | -26.64% | -32.30% | -30.28% | -9.23% | -15.89% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.65% | -4.04% | -6.33% | -4.29% | 7.51% |
| Operating Income | 100.65% | 81.37% | 39.27% | -4.79% | 319.61% |
| Income Before Tax | 26,784.91% | 188.80% | 124.82% | 37.58% | 99.37% |
| Income Tax Expenses | -677.27% | 12.73% | 114.18% | -110.47% | 173.33% |
| Earnings from Continuing Operations | 2,971.97% | 168.50% | 127.10% | 47.94% | 92.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1,292.09% | -224.60% | -121.24% | -54.06% | -86.22% |
| Net Income | 3,902.84% | 161.08% | 129.04% | 46.07% | 93.64% |
| EBIT | 100.65% | 81.37% | 39.27% | -4.79% | 319.61% |
| EBITDA | 73.27% | 22.62% | 15.76% | -1.00% | 68.11% |
| EPS Basic | 3,832.20% | 159.54% | 127.99% | 48.32% | 93.89% |
| Normalized Basic EPS | 251.23% | 322.88% | -57.33% | 23.64% | 173.26% |
| EPS Diluted | 3,645.76% | 158.88% | 127.44% | 48.32% | 93.89% |
| Normalized Diluted EPS | 239.88% | 316.34% | -58.62% | 23.64% | 173.26% |
| Average Basic Shares Outstanding | 2.39% | 2.55% | 3.81% | 4.15% | 3.73% |
| Average Diluted Shares Outstanding | 5.82% | 5.48% | 6.99% | 4.15% | 3.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |